Literature DB >> 1359888

Ursodeoxycholic acid-dependent activation of the glucocorticoid receptor.

H Tanaka1, I Makino.   

Abstract

Therapeutic effectiveness of ursodeoxycholic acid (UDCA) for primary biliary cirrhosis strongly indicates that UDCA possesses immunomodulatory activities. In order to further investigate mechanical background of such UDCA action, we first asked whether UDCA modulates glucocorticoid-mediated signal transduction. Using electrophoretic mobility-shift assay, we demonstrated that treatment with UDCA promoted the specific complex formation between the cytosol protein and the glucocorticoid-response element DNA in a dose-dependent fashion in vitro, and also nuclear translocation of the glucocorticoid receptor (GR) in vivo. Gene transfer experiments revealed that UDCA induced cellular CAT activities in a GR-dependent fashion, but rather weakly as compared to synthetic glucocorticoid dexamethasone.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1359888     DOI: 10.1016/0006-291x(92)91146-h

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  12 in total

1.  Severe hepatic injury caused by imatinib mesylate administered for the treatment of chronic myeloid leukemia and the efficacy of prednisolone for its management.

Authors:  Katsuya Ikuta; Yoshihiro Torimoto; Junko Jimbo; Junki Inamura; Motohiro Shindo; Kazuya Sato; Yoshihiko Tokusashi; Naoyuki Miyokawa; Yutaka Kohgo
Journal:  Int J Hematol       Date:  2005-11       Impact factor: 2.490

2.  Relative glucocorticoid potency revisited.

Authors:  H Tanaka; F Hirano; Y Nomura; T Miura; Y Makino; E Fukawa; I Makino
Journal:  Rheumatol Int       Date:  1994       Impact factor: 2.631

3.  Suppression of the HPA axis during extrahepatic biliary obstruction induces cholangiocyte proliferation in the rat.

Authors:  Matthew Quinn; Yoshiyuki Ueno; Hae Yong Pae; Li Huang; Gabriel Frampton; Cheryl Galindo; Heather Francis; Darijana Horvat; Matthew McMillin; Sharon Demorrow
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-10-06       Impact factor: 4.052

Review 4.  Nuclear receptors as therapeutic targets in cholestatic liver diseases.

Authors:  Gernot Zollner; Michael Trauner
Journal:  Br J Pharmacol       Date:  2009-01       Impact factor: 8.739

Review 5.  Novel strategies and therapeutic options for the management of primary biliary cholangitis.

Authors:  Amardeep Khanna; David E Jones
Journal:  Therap Adv Gastroenterol       Date:  2017-09-07       Impact factor: 4.409

6.  A dose-up of ursodeoxycholic acid decreases transaminases in hepatitis C patients.

Authors:  Shuichi Sato; Tatsuya Miyake; Hiroshi Tobita; Naoki Oshima; Junichi Ishine; Takuya Hanaoka; Yuji Amano; Yoshikazu Kinoshita
Journal:  World J Gastroenterol       Date:  2009-06-14       Impact factor: 5.742

Review 7.  Nuclear receptors as drug targets in cholestatic liver diseases.

Authors:  Emina Halilbasic; Anna Baghdasaryan; Michael Trauner
Journal:  Clin Liver Dis       Date:  2013-05       Impact factor: 6.126

Review 8.  Clinical application of transcriptional activators of bile salt transporters.

Authors:  Anna Baghdasaryan; Peter Chiba; Michael Trauner
Journal:  Mol Aspects Med       Date:  2013-12-12

Review 9.  Pediatric Cholestatic Liver Disease: Review of Bile Acid Metabolism and Discussion of Current and Emerging Therapies.

Authors:  Alyssa Kriegermeier; Richard Green
Journal:  Front Med (Lausanne)       Date:  2020-05-05

Review 10.  Bile acid transporters and regulatory nuclear receptors in the liver and beyond.

Authors:  Emina Halilbasic; Thierry Claudel; Michael Trauner
Journal:  J Hepatol       Date:  2012-08-08       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.